Pharming Group N.V. (PHAR) News
NASDAQ: PHARHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PHAR news summary
We found 13 recent headlines mentioning Pharming Group N.V. (PHAR): 0 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire. PHAR is making an outsized move today, down 5.10% at $11.54, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pharming Group N.V. headlines
- Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonPharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be availableGlobeNewswire
- MHRA Approves Pharming Group N.V.’s Joenja as First Treatment Specifically for Children with APDS in the U.K.Pharming Group N.V. announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of the marketing authorization of Joenja, an oral, selective…Nasdaq
- MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.GlobeNewswire
- Pharming: 3 Key Takeaways for Long-Term InvestorsKey PointsTotal third-quarter revenue increased 21% year over year to $117.6 million.Nasdaq
- Pharming (PHAR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberPharming Group N.V. reported its third quarter 2026 financial results, with total revenues increasing by 21% to US$117.6 million, compared to US$97.3 million in the third quarter of 2025. RUCONEST…Nasdaq
- Pharming Q3 Revenue Jumps 21%, CVID Data Due In November(RTTNews) - Pharming Group (PHAR) reported third quarter 2026 financial results, with double-digit revenue growth and higher profitability driven by continued demand for its rare disease therapies…NasdaqPHAR, ET
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberPharming Group N.V. presents its preliminary (unaudited) financial report for the third quarter ended September 30, 2026.GlobeNewswire
- Pharming Group Q3 Prel. Revenue Rises; Tightens FY26 Revenue Guidance(RTTNews) - Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary…NasdaqPHAR, ET
- Pharming Group announces third quarter 2026 revenues above market expectationsPharming announces preliminary, unaudited revenue and select financial information for Q3 2026 & full results brought forward to October 27, 2026.GlobeNewswire
- Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders(RTTNews) - Pharming Group N.V. (PHAR) reported positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies associated…NasdaqPHAR, ET
- Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary…Nasdaq
- Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026.GlobeNewswire